SCHEMBL25812739

SCHEMBL25812739

CC1=C(C)C(S(=O)(=O)c2ccccc2)c2ccc(N)cc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAT1 P18440 1/20 0.38
LMNA P02545 2/20 0.38
POLB P06746 2/20 0.37
HTR6 P50406 2/20 0.37
ALDH1A1 P00352 3/20 0.37
NPC1 O15118 2/20 0.37
TSHR P16473 2/20 0.37
RAB9A P51151 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
CYP3A4 P08684 2/20 0.37
CA12 O43570 2/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA4 P22748 2/20 0.37
CA9 Q16790 2/20 0.37
CA14 Q9ULX7 1/20 0.37
TP53 P04637 1/20 0.37
MAPK1 P28482 1/20 0.37
PTPRC P08575 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25812882 0.85 ELANE (0.39) LMNAALDH1A1SMN1; SMN2CA1CA2
SCHEMBL25811432 0.82 HTR6 (0.36) HTR6ALDH1A1CA12CA1CA2
SCHEMBL25811437 0.81 NAT1 (0.35) NAT1ALDH1A1RAB9ACA12CA1
SCHEMBL25811421 0.79 PTGS2 (0.46) LMNATSHRCA12CA1CA2
SCHEMBL16383945 0.68 ELANE (0.42) POLBALDH1A1CA12CA1CA2
SCHEMBL8970938 0.68 PDE10A (0.38) LMNAPOLBALDH1A1NPC1TSHR
SCHEMBL5554575 0.61 L3MBTL1 (0.59) LMNAPOLBHTR6ALDH1A1TSHR
SCHEMBL487472 0.60 LMNA (0.87) LMNAPOLBHTR6ALDH1A1TSHR
SCHEMBL19538864 0.60 GAA (0.36) LMNAPOLBHTR6ALDH1A1SMN1; SMN2
Benzene SCHEMBL27752989 0.59 LMNA (0.95) LMNAPOLBHTR6ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES GALYAN BIO INC (US) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230218573-A1 INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES HTT, HYPK, PARK7 NAT1 127/4885LMNA 2606/4885POLB 2897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.